K
Katherine G. Moss
Researcher at Celera Corporation
Publications - 6
Citations - 2418
Katherine G. Moss is an academic researcher from Celera Corporation. The author has contributed to research in topics: Receptor tyrosine kinase & Vascular endothelial growth factor. The author has an hindex of 6, co-authored 6 publications receiving 2352 citations.
Papers
More filters
Journal Article
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Dirk B. Mendel,A. Douglas Laird,Xiaohua Xin,Sharianne G. Louie,James G. Christensen,Guangmin Li,Randall E. Schreck,Tinya Abrams,Theresa J. Ngai,Leslie Lee,Lesley J. Murray,Jeremy P. Carver,Emily Chan,Katherine G. Moss,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Robert A. Blake,Li Sun,Cho Tang,Todd W. Miller,Sheri Shirazian,Gerald Mcmahon,Julie M. Cherrington +22 more
TL;DR: The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.
Journal ArticleDOI
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
Mary Ann Hardwicke,Catherine A. Oleykowski,Ramona Plant,Jamin Wang,Qiaoyin Liao,Katherine G. Moss,Ken A. Newlander,Jerry L. Adams,Dashyant Dhanak,Jingsong Yang,Zhihong Lai,David Sutton,Denis R. Patrick +12 more
TL;DR: Results show that GSK1070916 is a potent Aurora B/C kinase inhibitor that has the potential for antitumor activity in a wide range of human cancers.
Journal ArticleDOI
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Olga Potapova,A. Douglas Laird,Michelle Nannini,Angela Barone,Guangmin Li,Katherine G. Moss,Julie M. Cherrington,Dirk B. Mendel +7 more
TL;DR: The potent efficacy of SU11248 in models representing diverse signaling paradigms results from simultaneous inhibition of individual target receptors expressed both in cancer cells and in the tumor neovasculature, supporting the hypothesis that multitargeted inhibitors have the cumulative antitumor efficacy of combined single-target inhibitors.
Journal Article
Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
A. Douglas Laird,Guangmin Li,Katherine G. Moss,Robert A. Blake,Martin A. Broome,Julie M. Cherrington,Dirk B. Mendel +6 more
TL;DR: Data demonstrate that STAT3 (Y705) and FAK (Y861) phosphoepitopes are SFK-dependent in tumor cells and reveal a requirement for SFK function in tumor cell proliferation and vascular permeability.
Journal ArticleDOI
Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans
TL;DR: It is demonstrated that hair pigmentation can serve as a dose-dependent, dynamic, biological readout for KIT inhibition in mice, and, apparently, in humans.